PERBEDAAN RERATA KADAR CARBOXY TERMINAL PROPEPTIDE PROCOLLAGEN TYPE I (PICP) SERUM PADA PASIEN HIPERTENSI TANPA DAN DENGAN HIPERTROFI VENTRIKEL KIRI

• المؤلفون الرئيسيون: , dr. Agus Sutanto, , dr. Lucia Krisdinarti, SpPD-SpJP (K), FIHA
• التنسيق: Theses and Dissertations NonPeerReviewed
• منشور في: [Yogyakarta] : Universitas Gadjah Mada 2013
• الموضوعات: ETD
• الوصول للمادة أونلاين: https://repository.ugm.ac.id/119823/; http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=59828

Hypertension causes adverse changes in the structure and function of cardial as result of the increased afterload and neurohormonal and vascular changes. Hypertension causes hypertrophy concentric cardiac. Process hypertrophy causing maladaptive changes that occur in the extracellular matrix, as in cardiac myocytes, there is an increase of fibrillar collagen. Increased fibrillar collagen prevent normal contraction and relaxation of heart. Fibrillar collagen synthesized in the fibroblasts as procollagen consisting of the amino-terminal and carboxy-terminal propeptide. Carboxy-terminal propeptide procollagen type I (PICP) in the blood is cleaved from procollagen type I, so that serum levels of PICP reflect of tissue fibrosis. This study aimed to determine differences of PICP in hypertensive patients without and with LVH. The study design was cross-sectional in cardiology policlinic�s outpatients at Dr. Sardjito General Hospital Yogyakarta from August 2009 until the sample number is fulfilled. To analyze the difference between the two groups of hypertensive patients using the unpaired t test for normal distribution, while for abnormal distribution were analyzed with the Mann-Whitney U test. To analyze the normality of data conducted Kolmogorov-Smirnov test when the sample > 50 or Shapiro Wilk when the sample < 50. The differences of two groups of hypertensive patients considered as significant if p < 0.05 with confidence interval of 95%. The result showed 64 subjects divided the study subjects into two groups: subjects with hypertension without LVH (24 subjects) and with LVH (24 subjects) by echocardiography parameters. The baseline characteristics between groups of study subjects hypertension with and without LVH did not differ either in age, BMI, blood pressure, HR, duration of hypertension, laboratory parameter (Hb, leucocyt, trombocyt, BUN, creatinin, LDL, HDL, triglyceride, random glucose, GOT, GPT) except in sex. Baseline therapy characteristic as using of drugs such as ACEi, ARB, β-blocker, furosemide, CCB, spironolactone, thiazides, statins and drug combination. Levels of PICP in hypertensive subjects with LVH 846,44(617,05 � 945,61) ng / ml is higher than average levels of PICP in hypertensive subjects without LVH 816,26(614,37 � 916,45) ng / ml, but the difference in mean levels were not statistically significant (p = 0.177). Conclusion. There were no significant differences in the mean levels of serum PICP in hypertensive patients without LVH and hypertensive patients with LVH.